Sun Pharma Advanced Research Company Limited (SPARC.BO)
INR 145.7
(1.15%)
INR 145.7
(1.15%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.89 Billion INR | 22.67% |
| 2022 | 3.17 Billion INR | 27.52% |
| 2021 | 2.48 Billion INR | -37.46% |
| 2020 | 3.97 Billion INR | 36.65% |
| 2019 | 2.91 Billion INR | 184.82% |
| 2018 | 1.02 Billion INR | -17.61% |
| 2017 | 1.24 Billion INR | 8.48% |
| 2016 | 1.14 Billion INR | -12.58% |
| 2015 | 1.3 Billion INR | 205.24% |
| 2014 | 428.71 Million INR | -3.09% |
| 2013 | 442.4 Million INR | -56.01% |
| 2012 | 1 Billion INR | -33.95% |
| 2011 | 1.52 Billion INR | 111.06% |
| 2010 | 721.4 Million INR | 24.49% |
| 2009 | 579.47 Million INR | 123.95% |
| 2008 | 258.75 Million INR | 55.03% |
| 2007 | 166.9 Million INR | 200.36% |
| 2006 | 55.56 Million INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 3.98 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 3.35 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 3.89 Billion INR | 22.67% |
| 2023 Q4 | 3.89 Billion INR | 0.0% |
| 2022 Q2 | 4.11 Billion INR | 0.0% |
| 2022 Q4 | 3.17 Billion INR | 0.0% |
| 2022 FY | 3.17 Billion INR | 27.52% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q2 | 2.91 Billion INR | 0.0% |
| 2021 FY | 2.48 Billion INR | -37.46% |
| 2021 Q4 | 2.48 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q2 | 2.96 Billion INR | 0.0% |
| 2020 FY | 3.97 Billion INR | 36.65% |
| 2020 Q4 | 3.97 Billion INR | 0.0% |
| 2019 Q4 | 2.91 Billion INR | 0.0% |
| 2019 Q2 | 1.32 Billion INR | 0.0% |
| 2019 FY | 2.91 Billion INR | 184.82% |
| 2018 Q4 | 1.02 Billion INR | 0.0% |
| 2018 FY | 1.02 Billion INR | -17.61% |
| 2018 Q2 | 1.25 Billion INR | 0.0% |
| 2017 FY | 1.24 Billion INR | 8.48% |
| 2017 Q4 | 1.24 Billion INR | 0.0% |
| 2017 Q2 | 1.04 Billion INR | 0.0% |
| 2016 Q4 | 1.14 Billion INR | 0.0% |
| 2016 FY | 1.14 Billion INR | -12.58% |
| 2016 Q2 | 1 Billion INR | 0.0% |
| 2015 Q4 | 1.3 Billion INR | 0.0% |
| 2015 FY | 1.3 Billion INR | 205.24% |
| 2015 Q2 | 882.1 Million INR | 0.0% |
| 2014 Q4 | 428.71 Million INR | 0.0% |
| 2014 Q2 | 392.3 Million INR | 0.0% |
| 2014 FY | 428.71 Million INR | -3.09% |
| 2013 Q4 | 442.4 Million INR | 0.0% |
| 2013 Q2 | 909.2 Million INR | 0.0% |
| 2013 FY | 442.4 Million INR | -56.01% |
| 2012 FY | 1 Billion INR | -33.95% |
| 2012 Q4 | 1 Billion INR | 0.0% |
| 2011 Q4 | 1.52 Billion INR | 0.0% |
| 2011 FY | 1.52 Billion INR | 111.06% |
| 2010 FY | 721.4 Million INR | 24.49% |
| 2009 FY | 579.47 Million INR | 123.95% |
| 2008 FY | 258.75 Million INR | 55.03% |
| 2007 FY | 166.9 Million INR | 200.36% |
| 2006 FY | 55.56 Million INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 97.879% |
| NATCO Pharma Limited | 10.53 Billion INR | 63.037% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -91.37% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -234.094% |
| Achyut Healthcare Limited | 2.01 Million INR | -193287.978% |
| Ajanta Pharma Limited | 10.71 Billion INR | 63.653% |
| Alkem Laboratories Limited | 48.6 Billion INR | 91.991% |
| Alpa Laboratories Limited | 307.12 Million INR | -1167.542% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 76.079% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -6.331% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 97.442% |
| Bajaj HealthCare Limited | 4.86 Billion INR | 20.025% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -84.598% |
| Brooks Laboratories Limited | 248.6 Million INR | -1465.923% |
| Divi's Laboratories Limited | 18.99 Billion INR | 79.5% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 96.361% |
| Eris Lifesciences Limited | 38.26 Billion INR | 89.827% |
| FDC Limited | 3.7 Billion INR | -4.952% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 94.021% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | 24.861% |
| Granules India Limited | 22.95 Billion INR | 83.041% |
| Gufic Biosciences Limited | 5.59 Billion INR | 30.482% |
| Hester Biosciences Limited | 3.59 Billion INR | -8.295% |
| Indoco Remedies Limited | 10.34 Billion INR | 62.359% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -70.036% |
| Ipca Laboratories Limited | 33.74 Billion INR | 88.463% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -1211.801% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -30.902% |
| Lasa Supergenerics Limited | 541.92 Million INR | -618.347% |
| Laurus Labs Limited | 42.71 Billion INR | 90.886% |
| Lupin Limited | 96.23 Billion INR | 95.955% |
| Mankind Pharma Limited | 23.87 Billion INR | 83.694% |
| Medicamen Biotech Limited | 940.36 Million INR | -313.977% |
| Medico Remedies Limited | 438.24 Million INR | -788.295% |
| Megasoft Limited | 1.85 Billion INR | -110.07% |
| Piramal Pharma Limited | 74 Billion INR | 94.74% |
| RPG Life Sciences Limited | 1.38 Billion INR | -182.053% |
| Sigachi Industries Limited | 2.53 Billion INR | -53.793% |
| Unichem Laboratories Limited | 8.06 Billion INR | 51.756% |
| Wanbury Limited | 3.15 Billion INR | -23.368% |
| Windlas Biotech Limited | 1.76 Billion INR | -120.849% |
| ZIM Laboratories Limited | 2.08 Billion INR | -87.09% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 94.578% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -51.995% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -396.655% |
| Bal Pharma Limited | 2.51 Billion INR | -55.017% |
| Strides Pharma Science Limited | 37.68 Billion INR | 89.669% |
| Venus Remedies Limited | 1.39 Billion INR | -179.502% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 52.817% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 65.298% |
| Shilpa Medicare Limited | 12.93 Billion INR | 69.898% |
| Aarti Drugs Limited | 11.5 Billion INR | 66.16% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 38.49% |
| Suven Life Sciences Limited | 148.62 Million INR | -2519.347% |
| Ind-Swift Limited | 13.45 Billion INR | 71.063% |
| Valiant Laboratories Limited | 1.05 Billion INR | -267.859% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 63.645% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | 72.476% |
| Themis Medicare Limited | 1.88 Billion INR | -106.245% |
| Hikal Limited | 12.99 Billion INR | 70.043% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 95.255% |
| Sequent Scientific Limited | 8.27 Billion INR | 52.952% |
| Novartis India Limited | 1.8 Billion INR | -116.14% |
| Wockhardt Limited | 39.87 Billion INR | 90.236% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 93.647% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -1247.962% |
| Neuland Laboratories Limited | 5.49 Billion INR | 29.201% |
| Morepen Laboratories Limited | 4.45 Billion INR | 12.711% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -504.597% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -96.978% |